Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 74W in intermediate-stage hepatocellular carcinoma with TACE
jRCT2031200165Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of nivolumab and ipilimumab in hepatocellular carcinoma (HCC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Time to TACE progression and Overall survival. Started Nov 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031200165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200165.